2026年2月6日晚间，中国证监会更新了最新的境内中概股企业赴美上市名单（不包含已经备案通过的企业，也不包含秘交备案企业），已有53家企业由秘 交转公开，还有很大一部分企业在秘交中。截止目前，中概股企业赴美上市企业已递表排队侯场等持境外上市备案路条的近200家企业。2025年受CSRC 备案路条进度和SEC新政策提高首发募资要求，对中企赴上市速有所滞后影响，预计2026年4月特普朗访华后会有所改观。 ...

Group 1 - The core observation is that Chinese companies planning to go public in the U.S. in 2025 show a high concentration in their choice of listing venues, predominantly favoring Nasdaq [1] - Among the overall distribution of sectors, only one company from mainland China and two from Hong Kong opted for listing on NYSE MKT, while the majority are choosing Nasdaq [1] - Within Nasdaq, there is a notable tiered distribution: Bawang Chaji is listed on the Global Select Market, six companies are listed on the Global Market, and the vast majority are listed on the Capital Market [1]

Core Insights - A total of 71 Chinese concept stocks completed their listings in the U.S. by December 31, 2025, with 65 through traditional IPOs and 6 via SPAC mergers [1] - In 2024, 69 Chinese concept stocks went public in the U.S., with 61 through traditional IPOs and 8 through SPAC mergers [1] Fundraising Details - Among the 65 Chinese concept stocks that went public through traditional IPOs, only two raised over $100 million: Smithfield Foods, a spinoff of WH Group (2.6 billion USD), and Ascentage Pharma-B (1.26 billion USD) [1] - The majority of other companies raised amounts significantly below $20 million, with the largest share raising less than $10 million [1]

Core Insights - The willingness of Chinese companies to apply for listings in the U.S. has significantly rebounded in 2025, with a total of 80 companies submitting initial applications, marking an 11% increase from 72 in 2024 [1] Group 1: Listing Pathways - Traditional IPOs have become the dominant method for listings, with 71 companies planning to go public through this route, representing a substantial 29% year-on-year increase and serving as the main driver for the overall growth in applications [1] - The popularity of SPAC mergers has declined, with only 9 companies opting for this method, down from 17 in 2024, and all these companies plan to list on NASDAQ with valuations not exceeding $600 million [1] Group 2: Geographic Distribution - Over 60% of the applying companies are headquartered in Hong Kong, with 49 companies accounting for 61% of the total applications [1] - Among the applicants, there are 3 companies involved in VIE structures, as well as entities transitioning from A-shares, OTC markets, and Hong Kong's Growth Enterprise Market to NASDAQ [1] Group 3: Market Conditions - All companies are currently in the early stages of the listing application process, and the evolving global regulatory environment introduces significant uncertainty regarding the future listing timelines [1]

Group 1: A-Share Market Outlook - The A-share market is expected to see 114 companies listed by December 31, 2025, raising approximately 129.6 billion yuan, representing a 14% increase in new listings and a 94% increase in total financing compared to 2024 [1] - The ChiNext board is projected to have the highest number of new listings (19), while the Shanghai Stock Exchange is expected to lead in financing amount (43.2 billion yuan) [1] - The Shanghai Stock Exchange is anticipated to maintain its position as the fifth largest stock exchange globally, with a new stock financing amount of 80 billion yuan [1] Group 2: Hong Kong IPO Market Forecast - Hong Kong is projected to complete 114 new stock listings in 2025, raising around 286.3 billion HKD, which indicates a 63% increase in new listings and more than a twofold increase in financing compared to the previous year [2] - The positive outlook for Hong Kong's IPO market is attributed to various reforms, including simplified listing approval processes and the establishment of a special listing system for technology companies [2] - In 2026, approximately 160 new stocks are expected to be listed in Hong Kong, with total financing of at least 300 billion HKD, including seven stocks each raising at least 10 billion HKD [2] Group 3: U.S. Market for Chinese Companies - About 63 Chinese companies are expected to list in the U.S. in 2025, raising approximately 1.12 billion USD, which is a 7% increase in the number of new listings but a 41% decrease in financing compared to 2024 [3] - The largest two Chinese companies listed in the U.S. this year are from the consumer and pharmaceutical sectors [3] - There is a cautious outlook for Chinese companies listing in the U.S. in 2026, particularly if proposed listing thresholds by Nasdaq are approved, which may lead to a decrease in the number of eligible Chinese companies [3]

Core Viewpoint - The OTC market is emerging as a viable alternative for Chinese companies seeking to list in the U.S., offering more flexible listing conditions compared to traditional exchanges like NASDAQ and NYSE. Group 1: Financial Conditions - The OTC market has no strict profitability requirements, allowing companies in R&D or market expansion phases to attract early investors based on their innovative potential and technological advantages [1] - NASDAQ requires a minimum cumulative pre-tax income of $11 million over the last three years and at least $2.2 million in the last two years, which poses a significant barrier for many high R&D investment companies [1] Group 2: Market Capitalization and Cash Flow - NASDAQ typically mandates a minimum market capitalization of $75 million and certain cash flow standards, while the OTC market does not impose uniform hard requirements, thus providing access for smaller companies with unstable cash flows but growth potential [2] Group 3: Share Structure and Shareholder Distribution - The OTC market has lower public shareholding and shareholder number requirements compared to NASDAQ, which requires a public market value of at least $125 million and at least 400 shareholders holding over 100 shares [4] - This flexibility allows companies to focus more on business development without excessive early-stage equity dilution [4] Group 4: Compliance and Information Disclosure - The OTC market offers a simplified disclosure process, reducing compliance costs and allowing companies to allocate more resources to operations and development, in contrast to NASDAQ's strict and complex disclosure requirements [7] Group 5: Corporate Governance - The OTC market provides more transitional space for corporate governance, allowing companies to gradually improve their governance structures, unlike NASDAQ, which has specific requirements for independent board members and committee setups [8] Group 6: Summary of OTC's Position and Value - Overall, the OTC market is more inclusive in terms of profitability thresholds, market capitalization requirements, share flexibility, and compliance costs compared to traditional exchanges [10] - For Chinese companies, the OTC market serves as a flexible international capital starting point, a bridge connecting early-stage companies with global funding, and a strategic channel for growth, transition, and sustainable expansion [10]

Core Insights - As of December 12, 2025, the China Securities Regulatory Commission (CSRC) has received a total of 884 applications for overseas initial public offerings (IPOs) from domestic companies, with 405 companies obtaining relevant approval notices [1] - During the period from December 8 to December 12, 2025, 55 companies applied for U.S. listings, and 14 companies received overseas issuance listing approval notices [2] - The approval of Longdian Huaxin New Energy Technology Group's overseas issuance listing on December 11, 2025, marks the resumption of the channel for Chinese concept stocks to list in the U.S. since April 2025 [4][5] Summary by Category Overseas IPO Applications - A total of 884 domestic companies have submitted applications for overseas IPOs, with 405 receiving approval [1] - The breakdown of applications includes 717 for the Hong Kong Stock Exchange, 5 for the New York Stock Exchange, 150 for the Nasdaq, 8 for the Taiwan Stock Exchange, and others for various international exchanges [1] Recent Developments - In the week from December 8 to December 12, 2025, 55 companies applied for U.S. listings, with 14 receiving approval [2] - The approval of Longdian Huaxin New Energy Technology Group is seen as a positive signal for the normalization of the overseas listing mechanism for Chinese companies [5] Company Listings - Companies such as GoodFaith Technology Inc., Lemeng Holdings Limited, and MED EIBY Holding Co., Limited are among those applying for indirect overseas listings on the Nasdaq [3] - The list of companies includes various sectors, primarily in industrial manufacturing and technology [6]

Group 1 - The core message of the news is the reactivation of the channel for Chinese companies to list in the U.S., symbolized by the approval of Longdian Huaxin's overseas issuance and listing [1][2] - Longdian Huaxin plans to raise approximately $500 million, marking it as one of the larger recent IPO cases for Chinese companies [2] - The approval is seen as a significant policy signal, indicating a more open attitude from regulatory authorities towards eligible companies seeking to list abroad [2][3] Group 2 - Contrary to popular belief, the channel for Chinese companies to list in the U.S. has not been completely closed, although the scale and structure have changed [3] - In the first half of 2025, 36 Chinese companies successfully listed in the U.S., continuing the trend from 64 listings in 2024, primarily in sectors like new energy, biotechnology, and consumer goods [3] - There are still over 40 Chinese companies in the queue to apply for listing on NASDAQ, indicating ongoing interest in U.S. capital markets [3] Group 3 - More Chinese companies are adopting dual listing structures, such as "U.S. + Hong Kong," to leverage high liquidity in the U.S. market while connecting with domestic investors [4] - The number of companies waiting for IPOs in Hong Kong has exceeded 160, reflecting the market's continued attractiveness [4] - The core goal of returning to the Hong Kong market is to enhance stock trading stability and security, maximizing shareholder value [4] Group 4 - The approval for Longdian Huaxin marks a new phase in the global capital layout for Chinese companies, with balance and diversity becoming core characteristics [6] - The U.S. capital market is considering raising the IPO fundraising threshold to $25 million, which will impose higher requirements on Chinese companies [6] - The chairman of the China Securities Regulatory Commission has stated that conditions will be created to support quality Chinese companies returning to domestic and Hong Kong markets, fostering a complementary relationship between domestic and foreign markets [6] Group 5 - The excitement in the financial community reflects a desire for the return of institutional certainty, with Longdian Huaxin's approval creating ripples in the market [8] - Chinese companies are reassessing the global capital market, viewing it as a multi-faceted balancing act rather than a binary choice [9]

Group 1: Policy Environment - The regulatory environment in China is shifting from a focus on risk prevention to a balanced approach of regulation and support, providing clearer guidelines for companies seeking to list abroad [2] - Chinese regulatory authorities are optimizing overseas listing management rules, clarifying compliance paths in sensitive areas like data security and VIE structures, which reduces uncertainty for eligible companies [2] - In the U.S., there is a subtle change in the attitude towards IPOs, with regulatory bodies showing increased acceptance of companies in innovative sectors like technology and biomedicine, effectively lowering listing thresholds for these industries [2] Group 2: Market Sentiment - Chinese concept stocks have shown strong performance, with the Nasdaq Golden Dragon China Index experiencing a notable rebound, and many companies reaching historical highs in stock prices [4] - The robust earnings growth of leading companies in new economic sectors such as consumption upgrade, technological innovation, and green energy has supported stock prices amid macroeconomic concerns [4] - Global liquidity is improving as major central banks, particularly the Federal Reserve, shift towards a rate-cutting cycle, leading to a search for high-growth investment opportunities, making U.S.-listed Chinese concept stocks attractive [4] Group 3: Future Challenges - The current favorable conditions should not be seen as a clear path forward, as regulatory cooperation between China and the U.S. still requires time to stabilize [6] - Ongoing compliance costs and potential regulatory scrutiny remain challenges for companies planning to go public [6] - Investors in the U.S. are becoming more selective, requiring companies to demonstrate strong technical capabilities, clear profit pathways, and sound corporate governance to achieve true value recognition [6]

Group 1 - The core viewpoint is that geopolitical tensions have not hindered Chinese companies from listing in the U.S., with a record number of listings expected in 2024 and 2025 [2] - In 2024, 64 Chinese companies have already listed in the U.S., and 36 more are expected in the first half of 2025, primarily small and medium-sized enterprises, many utilizing SPACs to expedite the process [2] - Over 40 Chinese companies are currently waiting to list on NASDAQ, driven by stricter domestic listing regulations and the attractive valuations in the U.S. market [2] Group 2 - In July 2025, 13 Chinese companies successfully listed in the U.S., all on NASDAQ [3] - The financing landscape for Chinese companies listing in July showed significant stratification, reflecting the flexibility of U.S. capital tools and differing financing strategies among companies [5][11] Group 3 - The SPAC model has emerged as a leading capital tool in the U.S., with A Paradise Acquisition raising $200 million, accounting for over 69% of the total IPO scale for Chinese companies during the same period [6][11] - Companies like Youlan International and Meihua Chuangfu are focusing on core sectors, raising $27 million and $15 million respectively, indicating a trend towards securing funds for technology development and market expansion [8] Group 4 - Smaller companies are adopting a "lightweight listing" strategy, with firms like Weimei Holdings and Anba Finance raising $2.5 million and $5 million respectively, prioritizing brand exposure and flexible post-listing financing [9] - The differentiation in fundraising among Chinese companies is influenced by industry attributes and listing models, with emerging industries attracting more capital due to clear growth potential [11] Group 5 - Foreign institutions are becoming more optimistic about Chinese stocks, as evidenced by the 16.76% increase in the NASDAQ Golden Dragon China Index since the beginning of the year, outperforming major U.S. indices [12] - Approximately 72% of Chinese companies choose to list on NASDAQ, favoring technology and growth-oriented firms, while 25% opt for the NYSE, primarily for established industry leaders [12][13]